Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib in resected BRAF-mutant melanoma
NCT01667419Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2012
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of vemurafenib in cutaneous melanoma (CM), sponsored by Roche. Started Sep 2012; status: completed.
02
Drugs
vemurafenib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT01667419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01667419.